Research progress on PD-1/PD-L1 inhibitors in prostate cancer immunotherapy
10.3969/j.issn.1000-8179.2017.16.336
- VernacularTitle:PD-1/PD-L1抑制剂在前列腺癌免疫治疗中的研究进展
- Author:
Yi YANG
- Keywords:
prostate cancer;
immunotherapy;
immune checkpoint;
PD-1/PD-L1 inhibitors
- From:
Chinese Journal of Clinical Oncology
2017;44(16):831-834
- CountryChina
- Language:Chinese
-
Abstract:
The annual incidence of prostate cancer (PCa) continually increases. New PCa immune therapy has become the fourth line antitumor treatment following surgery, radiotherapy and chemotherapy. As the most promising research direction in cancer immunotherapy,immune checkpoint inhibitors, such as programmed cell death-1 and programmed cell death-ligand 1 (PD-1/PD-L1) inhibitors, block PD-1 and its ligand PD-L1 and then terminate the negative control signal to the T cell, thereby facilitating T cell recovery and reversal of tumor immune-escaping mechanism. These processes restore the capability of T cells for immune response and inhibit and kill tumor cells. This review summarizes the progress on the current application of PD-1/PD-L1 inhibitors in PCa clinical trials.
